与明基医院签8年长期协议引关注，合富中国回复监管工作函

Core Viewpoint - The long-term procurement agreement between HeFu China and Mingji Hospital is based on strategic alignment and historical procurement data, with a minimum purchase amount of 600 million yuan over 8 years [1][2]. Group 1: Agreement Details - The long-term procurement agreement stipulates that Mingji Hospital will purchase in vitro diagnostic reagents and consumables from HeFu China, with a total minimum purchase amount of 600 million yuan over 96 months [1]. - The agreement includes exclusive supply arrangements, which may be affected by changes in the competitive environment [1]. - The minimum purchase amount is based on historical procurement data from Mingji Hospital, indicating a strong alignment with past purchasing patterns [2]. Group 2: Financial Implications - Mingji Hospital's procurement costs for drugs and medical consumables from 2022 to 2024 are projected to be 896 million yuan, 1.056 billion yuan, and 1.034 billion yuan, respectively, with a compound annual growth rate of 7.2% [2]. - The minimum purchase amount agreed upon is significantly lower than Mingji Hospital's total procurement costs, suggesting clear commercial rationale [2]. - The long-term agreement is expected to positively impact HeFu China's revenue, with the agreement amount accounting for over 50% of the company's most recent revenue [4]. Group 3: Risks and Management - The feasibility of achieving the minimum purchase amount is a key concern, with HeFu China citing historical data and expansion plans as supportive factors [3]. - The company acknowledges potential uncertainties due to market adjustments and macro policies, which could affect the realization of the minimum purchase amount [3]. - HeFu China plans to conduct annual reviews with Mingji Hospital to monitor procurement execution and address any emerging risks [3]. Group 4: Company Performance - HeFu China is facing its first loss since going public, with a projected net profit of -36 million to -25 million yuan for 2025, primarily due to domestic medical policy impacts and declining product prices [3]. - Despite the current challenges, HeFu China anticipates that its investments in intelligent products will drive future growth, unaffected by government procurement policies [3].